2011
DOI: 10.4067/s0716-10182011000600001
|View full text |Cite
|
Sign up to set email alerts
|

Susceptibilidad in vitro a anidulafungina en 100 cepas de especies de Candida aisladas previo a la introducción de esta equinocandina en Chile

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…The epidemiology of these candidiases is very dynamic as the prevalence of Candida species varies in different geographical areas, kinds of patients and hospital types [ 3 ]. One of the major problems of these diseases is the high frequency of non- albicans Candida species that present intrinsic or secondary resistance to various antifungals, narrowing medical treatment alternatives and increasing the chances of morbidity and mortality [ 4 ]. Today, there is an expected global epidemic of C. auris in health care settings with high mortality and multidrug resistance characteristics, with 93% of isolates resistant to fluconzazole, 35% to amphotericin B, 7% to echinocandin, 42% to two or more antifungal classes and 4% to all antifungal classes.…”
Section: Introductionmentioning
confidence: 99%
“…The epidemiology of these candidiases is very dynamic as the prevalence of Candida species varies in different geographical areas, kinds of patients and hospital types [ 3 ]. One of the major problems of these diseases is the high frequency of non- albicans Candida species that present intrinsic or secondary resistance to various antifungals, narrowing medical treatment alternatives and increasing the chances of morbidity and mortality [ 4 ]. Today, there is an expected global epidemic of C. auris in health care settings with high mortality and multidrug resistance characteristics, with 93% of isolates resistant to fluconzazole, 35% to amphotericin B, 7% to echinocandin, 42% to two or more antifungal classes and 4% to all antifungal classes.…”
Section: Introductionmentioning
confidence: 99%